Regulonix LLC
Gainesville, FL Regulonix, LLC
- UEI
- RZ32MNG7DH93
- CAGE
- 7HRZ9
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 2878 SW 106th St, Gainesville, FL 32608, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Targeting the neuropilin-1 receptor (NRP-1)/vegf-a axis for neuropathic pain - abstract revisions noted in blue font… | National Institute of Neurological Disorders and Stroke | $1,258,410 | |
| Inhibition of CAV?-? Interaction with orally available small organic molecules for chronic pain - abstract revisions… | National Cancer Institute | $1,074,040 | |
| Discovery of t-type calcium channel antagonists from multicomponent reactions and their application in… | National Institute of Neurological Disorders and Stroke | $341,527 | |
| Optimization of betulinic acid analogs for t-type calcium channel inhibition for non-addictive relief of chronic pain | National Institute on Drug Abuse | $224,696 | |
| Regulators of NAV1.7 channels: novel anti-allodynic drug candidates | National Institutes of Health | $299,999 |
About Regulonix LLC
Regulonix LLC is a for-profit limited liability company that provides research and development services to the federal government through grant awards from the National Institutes of Health (NIH). Regulonix partners with universities and other organizations to discover and develop novel therapeutics, with a focus on treating chronic pain conditions.
Through prime and sub federal grant awards, Regulonix has provided research services aimed at identifying and characterizing potential drug candidates that target mechanisms involved in neuropathic and chemotherapy-induced peripheral neuropathy pain. Specifically, Regulonix has performed in vitro and in vivo efficacy studies, early ADME profiling, off-target screening, and preclinical pain model testing on compounds targeting neuropilin-1 receptors, T-type calcium channels, and N-type calcium channels. Regulonix has partnered with the University of Arizona under NIH National Institute of Neurological Disorders and Stroke and National Cancer Institute grant programs. Additionally, Regulonix has received direct NIH National Institute on Drug Abuse and National Institute of Neurological Disorders and Stroke grants to optimize lead compounds and compound series for advancement as non-addictive chronic pain therapies.
Quick answers
What is Regulonix LLC's UEI?
Regulonix LLC's Unique Entity ID (UEI) in SAM.gov is RZ32MNG7DH93.
What is Regulonix LLC's CAGE code?
Regulonix LLC's CAGE code is 7HRZ9.
What is Regulonix LLC's primary NAICS code?
Regulonix LLC's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Regulonix LLC located?
Regulonix LLC's physical address in SAM.gov is 2878 SW 106th St, Gainesville, FL 32608, USA.
Is Regulonix LLC registered in SAM.gov?
Yes. Regulonix LLC's SAM.gov registration is active through July 8, 2027.
What is Regulonix LLC's most recent federal award?
Regulonix LLC's most recent federal grant award is Targeting the neuropilin-1 receptor (NRP-1)/vegf-a axis for neuropathic pain - abstract revisions noted in blue font… (R41NS122545), from National Institute of Neurological Disorders and Stroke, on September 1, 2021.
On GovTribe
See Regulonix LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors